Consultancy | pharmaphorum

Skip to main content

Wednesday 6 December 2023

twitter linkedin facebook rss

User account menu

Sign up

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Consultancy

News

Andy Zoltners

ZS mourns death of co-founder Andy Zoltners

The biopharma industry has lost another leading figure with the passing of Andy Zoltners, co-founder of ZS Associates, on the 40th anniversary of the company.

News

Blake Dark

Ex-NHS chief negotiator joins Newmarket Strategy

Two years after co-founding healthcare and life sciences consultancy Newmarket Strategy, former UK Health Minister Lord James O’Shaughnessy has recruited Blake Dark, previ

Partner Content

2020-01 LinkedIn - I&I Leadership

Partner Content

Prescient Intelligence & Insight announces recent appointmen...

Prescient hires three new senior members to strengthen and grow its Intelligence & Insight business

Partner Content

Face to face and online training

Partner Content

J+D and the University of Bath School of Management Collabor...

J+D recently provided forecasting training materials to the Strategy & Organisation Division of the University of Bath School of Management.

Editor's Picks

AbbVie agrees $10.1bn deal to buy ImmunoGen

UK Biobank releases largest-ever genome sequencing dataset

EVERSANA brings GenAI to medical content approvals

Experts allay fears over pneumonia outbreak in China

Could high HDL-cholesterol raise dementia risk?

News

Taisho says $5bn management buyout will rev up business

Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi

live

R&D

Revolutionising research: Inside the NCVR evolution in the UK

Sponsored

Revolutionising research: Inside the NCVR evolution in the U...

On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company